Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
MWN-AI** Summary
Molecular Partners AG, a clinical-stage biotech company focused on innovative DARPin therapeutics, held its Annual General Meeting (AGM) on April 14, 2026, in Zurich-Schlieren, Switzerland. The company announced the successful approval of all board proposals, including the election of Clare Fisher as a new board member, following a decisive vote by shareholders. Fisher, who currently serves as Senior Vice President for Global Business Development and M&A at BeOne Medicines, brings over two decades of extensive experience in the pharmaceutical industry, which is expected to significantly benefit Molecular Partners as it expands its pipeline of drug candidates.
Chairman Bill Burns highlighted Fisher's qualifications, noting the importance of her corporate development expertise to the company's partnerships. The AGM also addressed the approval of financial statements for the fiscal year 2025, which reported a net loss of CHF 57.85 million, increasing the total carried forward loss to CHF 257.29 million. Despite the financial challenges, shareholders granted discharge to the Board of Directors for the financial year 2025 and re-elected all members for another term, reaffirming confidence in the management team.
Notably, Steven H. Holtzman did not seek re-election after 12 years of service on the Board. KPMG AG Zurich and Anwaltskanzlei Keller AG were re-elected as statutory auditors and independent proxy, respectively. Additionally, the AGM approved all motions regarding compensation for both the Board and Management.
Molecular Partners, with its dual headquarters in Switzerland and Massachusetts, continues to pursue pioneering therapies for cancer, leveraging its unique DARPin technology. For further details on the company's ongoing projects and future outlook, stakeholders are encouraged to visit their website or reach out to corporate communications.
MWN-AI** Analysis
Molecular Partners AG's recent Annual General Meeting (AGM) revealed several significant developments that investor sentiment may want to capitalize on. The election of Clare Fisher to the Board of Directors marks a strategic enhancement, considering her extensive experience in business development within the pharmaceuticals and biotechnology sectors. This move aligns with the company’s goal to expand its pipeline of DARPin therapeutics, addressing unmet medical needs.
Shareholder approval of board proposals, including compensation reports, indicates strong confidence in the current leadership and strategic direction. Importantly, the acceptance to carry forward a net loss of CHF 257,293,925 signals an understandable commitment to long-term growth, though it does pose questions about short-term profitability. Investors should note that this financial posture might lead to increased scrutiny on the company’s future funding requirements and operational efficiency.
Molecular Partners remains focused on innovative drug development, tackling areas difficult for existing treatment modalities to address, particularly in oncology. The firm has a solid portfolio in various clinical stages that could translate into lucrative partnerships, a key area where Fisher's expertise will likely prove beneficial. Given the volatility often intrinsic to biotech stocks, and Molecular Partners' history of losses, investors must adopt a discerning approach—monitoring both clinical trial outcomes and broader market conditions impacting biotechnology more broadly.
Investors should engage closely with ongoing financial reports and updates from clinical trials. Given the high risk-reward nature of biotech investments, identifying future catalysts—such as clinical trial milestones or strategic partnerships—will be critical for making informed equity positions in Molecular Partners. Clarity around cash runway for 2026 is essential in assessing the likelihood of additional financing needs that could impact equity dilution. Overall, this AGM signals positive governance changes, but investors should proceed cautiously, balancing the potential for growth against inherent biotech risks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that Clare Fisher was elected by shareholders to its Board of Directors at the Annual General Meeting (AGM).
The appointment, and all other motions proposed by the Board of Directors at the AGM, were approved by the shareholders of the Company by a wide majority.
“Clare Fisher is an outstanding addition to our Board and we warmly welcome her. Clare’s extensive business and corporate development experience in the pharmaceutical and biotech industry will be valuable for our partnerships and expanding pipeline of new drug candidates,” said Bill Burns, Chairman of the Board of Directors of Molecular Partners.
Clare Fisher is currently the SVP for Global Business Development and M&A at BeOne Medicines, a global oncology company committed to discovering and developing innovative treatments for cancer patients worldwide. Clare has more than two decades of healthcare experience in leadership roles, including corporate and business development, mergers and acquisitions, and strategy. She joined BeOne from Kaleido, where she served as Chief Business Officer. Previously Clare worked at Shire plc (now Takeda), where she was Group Vice President, Global Head of Transactions and Business Development, and Interim Head of Corporate Development. She also held senior roles in business development at Cubist Pharmaceuticals, Blueprint Medicines, and Genzyme Corporation. Clare Fisher earned a B.S. in biochemistry from the University of Bath and an MBA from Henley Management College in the U.K.
The Molecular Partners shareholders confirmed the approval of the annual review, the IFRS consolidated financial statements and the annual statements for the financial year 2025. They also approved the consultative vote on the compensation report and the proposal to carry forward, and not to offset, the net loss for 2025 of CHF 57,853,768, thereby bringing the loss carried forward position from CHF 199,440,157 to CHF 257,293,925.
The Board of Directors and the members of the Management Board were granted discharge for the financial year 2025. Steven H. Holtzman did not stand for re-election following 12 years of service on the Board of Directors. The shareholders voted to re-elect all other members of Molecular Partners’ Board of Directors for a term of office of one year. William “Bill” Burns was re-elected as Chairman of the Board and re-appointed as the chairperson of the Board’s Nomination and Compensation Committee. Michael Vasconcelles, M.D., was re-elected to the Nomination and Compensation Committee. Agnete Fredriksen was elected to the Nomination and Compensation Committee, in place of Steven H. Holtzman.
KPMG AG Zurich was re-elected as the Group’s statutory auditors for the financial year 2026 and Anwaltskanzlei Keller AG, Zurich, was re-elected as the independent proxy for a term of office until the 2027 Annual General Meeting.
The AGM also approved all binding motions regarding compensation for both the Board of Directors and the Management Board.
About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs
For further details, please contact:
Seth Lewis, EVP Corporate Finance
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; the expected benefits of the strategic review; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, “anticipate”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth in under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.
Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ**
How does the election of Clare Fisher to the Board of Directors at Molecular Partners AG MLLCF impact the company's strategic direction and potential partnerships in the biotech industry?
Considering the continuous financial losses reported by Molecular Partners AG MLLCF, what strategic measures are being implemented to improve the company’s financial outlook for 20and beyond?
With the company’s focus on DARPin therapeutics, how does Molecular Partners AG MLLCF plan to differentiate its offerings from other established cancer treatments currently in the market?
What are the anticipated timelines and expected outcomes for Clinical Trials of Molecular Partners AG MLLCF’s product candidates following the recent AGM approvals and the ongoing development programs?
**MWN-AI FAQ is based on asking OpenAI questions about Molecular Partners AG (OTC: MLLCF).
NASDAQ: MLLCF
MLLCF Trading
-1.04% G/L:
$3.80 Last:
3,534 Volume:
$3.84 Open:
MLLCF Latest News
